| NATIONAL CANCER CENTER Patent applications |
| Patent application number | Title | Published |
|---|
| 20120068631 | CHARGED PARTICLE BEAM RADIATION CONTROL DEVICE AND CHARGED PARTICLE BEAM RADIATION METHOD - Provided is a charged particle beam radiation control device that controls radiation of a charged particle beam, the charged particle beam radiation control device including: a controller which controls an acceleration voltage for accelerating charged particles, wherein the controller includes a set acceleration voltage controller which selects a non-radiation state of a charged particle beam by setting an acceleration voltage of a radiation state of the charged particle beam to a reference acceleration voltage and changing the acceleration voltage to a set acceleration voltage larger or smaller than the reference acceleration voltage. | 03-22-2012 |
| 20110287036 | NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND - The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker. | 11-24-2011 |
| 20110262425 | THERAPEUTIC AGENT FOR MLL LEUKEMIA AND MOZ LEUKEMIA OF WHICH MOLECULAR TARGET IS M-CSF RECEPTOR, AND USE THEREOF - An objective of the present invention is to provide therapeutic agents for MLL leukemia and MOZ leukemia, which include an M-CSF receptor inhibitor as an active ingredient. Another objective of the present invention is to provide methods of screening for pharmaceutical compositions that treat or prevent leukemia by suppressing the expression or activity of M-CSF receptor. Still another objective of the present invention is to provide methods of testing for leukemia, which include the step of determining the expression level of an M-CSF receptor. The present inventors conducted dedicated studies, and as a result revealed that the M-CSF receptor (M-CSFR, CSF1R, c-FMS, or CD115) is highly expressed in cells having the activity of inducing MLL or MOZ leukemia (leukemia stem cells), both of which are intractable acute leukemia. Specifically, the present inventors discovered that the M-CSF receptor signal is closely associated with the leukemia onset. | 10-27-2011 |
| 20110250584 | Method for Screening Cancer Therapeutic Agent Using Galectin-3, GSK-3Betta, and Fascin-1 - Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3β. | 10-13-2011 |
| 20110152121 | APPARATUS AND METHOD FOR MULTIPLE IMMUNOASSAYS ON A CHIP - Provided are a multiple immunoassay apparatus on a chip in which a structure comprising multiple microfluidic channels is associated with a tissue sample, which allows immunohistochemical reactions to be conducted therein, to examine various markers specific for certain diseases, and a method for performing multiple immunoassays using the same. The multiple immunoassay apparatus comprises: at least one antibody-introducing unit through which at least one antibody is introduced into the apparatus; at least one reaction unit in which the antibody reacts with a sample in an immunohistochemical pattern; and at least one fluid outlet through which a fluid including the antibody is discharged outside the apparatus. | 06-23-2011 |
| 20110150869 | Neuroinvasion Inhibitor - The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice. | 06-23-2011 |
| 20110136246 | NOVEL ONCOGENE NRF2 - The present invention provides a marker which can be used as an indicator for efficacy prediction of an mTOR related anticancer agent or prognostic prediction, and a novel anticancer agent. The present invention provides a method for efficacy evaluation of a cancer drug, and, specifically, a prediction method for the efficacy of an mTOR-related cancer drug by detecting NRF2 abnormality. In addition, the present invention provides a prognostic prediction method for cancer, and, specifically, a prediction method for the prognosis of cancer by detecting NRF2 abnormality. Furthermore, the present invention provides a novel anticancer agent that targets NRF2. | 06-09-2011 |
| 20110124712 | ANTI-CANCER COMPOSITION COMPRISING MICRORNA MOLECULES - Disclosed is an anticancer composition for the treatment of hypoxia-induced angiogenesis-associated diseases including cancers. It comprises a microRNA-125 nucleic acid molecule. Also, methods of inhibiting angiogenesis, suppressing the invasion and metastasis of cancer cells, and treating cancers are provided. | 05-26-2011 |
| 20110105352 | METHOD FOR MEASURING CHROMOSOME, GENE OR SPECIFIC NUCLEOTIDE SEQUENCE COPY NUMBERS USING SNP ARRAY - The present invention relates to a method for measuring the copy number of a chromosome, gene or specific nucleotide sequence, comprising the steps of: (a) mixing a homozygous DNA with a test sample DNA; (b) analyzing the DNA mixture by means of SNP array; and (c) determining the copy number of a chromosome, gene, or specific nucleotide sequence by measuring the difference in signal output from the homozygous DNA and the test sample DNA. | 05-05-2011 |
| 20110091471 | TREATMENT METHOD FOR EPITHELIAL CANCEROUS ORGANISM - It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising:
| 04-21-2011 |
| 20110028535 | OLIGONUCLEOTIDES-TRANSFERRING PREPARATIONS - Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided. | 02-03-2011 |
| 20110021601 | COMPOSITION CONTAINING MICRORNA-21 INHIBITOR FOR ENHANCING RADIATION SENSITIVITY - Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the therapeutic effect of such irradiation on cancer high in microRNA-21 expression level, particularly, glioma. | 01-27-2011 |
| 20100316635 | KIT FOR DIAGNOSIS OF BREAST CANCER USING HERCEPTIN, A COMPOSITION COMPRISING HERCEPTIN AND A METHOD FOR DETECTING HERCEPTIN-SENSITIVE HER2 OVEREXPRESSED CELL USING THE SAME - A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided. | 12-16-2010 |
| 20100286675 | Surgical instrument - Provided is surgical instrument which can provide a field of view over surgical site by sucking blood from bleeding site during surgery on body tissue of patient and monitoring dark and deep surgical site, which operator cannot see with his or her naked eye, with small camera. The surgical instrument has substantially the same shape as a pair of scissors and includes first body, second body having shape symmetrical to that of the first body, hinge to which the first and second bodies cross and are rotatably coupled, and photographing unit provided in the hinge to photograph a surgical site between front ends of the first and second bodies. The photographing unit may include camera mounted in the hinge such that lens of the camera can be exposed through the center of the front surface of the hinge and configured to transmit photographed image data to monitor. | 11-11-2010 |
| 20100274097 | Surgical instrument - Provided is a surgical instrument which can provide a field of view over a surgical site by sucking blood from a bleeding site during surgery such as tissue dissection and illuminating a dark and deep surgical site. The surgical instrument includes a first body including at least one suction port provided at a front end thereof, a second body configured to cross the first body and to be rotatably coupled to the first body, a suction unit provided in the first body to suck blood from a bleeding site of a patient through the suction port during surgery, and an illuminator provided in the second body to illuminate a space between front ends of the first and second bodies. | 10-28-2010 |
| 20100230259 | PEDAL INPUT DEVICE WITH THREE ROTATIONAL DEGREES OF FREEDOM - A pedal input device includes a base plate; a rotation center portion provided at the center of the base plate; a contacting plate having a yaw switch contacting portion protruding downwards from lower surface of the contacting plate; a pedal plate carried by the contacting plate and foot-operated so as to cause a drive member to make three-degree-of-freedom movement; a pair of pitch switches installed on the base plate in an opposing relationship with each other; a pair of roll switches installed on the base plate in an perpendicular relationship to the pitch switches so that the roll switches can be alternately contacted to the contacting plate of the pedal plate; and a pair of yaw switches installed on the base plate in an spaced-apart relationship with each other so that the yaw switches can be alternately contacted to the yaw switch contacting portion as the pedal plate rotates. | 09-16-2010 |
| 20100016249 | CANCER SENSITIZER COMPRISING GLUCOSAMINE, GLUCOSAMINE DERIVATIVES OR SALTS THEREOF - Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy. | 01-21-2010 |
| 20090318981 | PIN ASSEMBLY FOR OPERATION - A pin assembly for operation includes a hollow pin for operation having a plurality of side holes defined through a wall thereof and a root part which is closed or open due to the presence of a through-hole; and a hollow support member having a pin fastening part formed therein in the shape of a groove to fasten one end of the pin for operation, and being open at both ends thereof, wherein the pin for operation is fastened to the pin fastening part of the support member, and by applying external force to one end of the support member, the pin for operation is inserted into a bone. | 12-24-2009 |
| 20090257639 | METHOD OF TRACKING EYEBALL IN EYEBALL TUMOR TREATMENT - Disclosed herein is a method of tracking the movement of an eyeball in eyeball tumor treatment. The method includes a calibration step of storing an actual length for each pixel of an image in a storage unit, a template image generation step of storing a patient's eyeball image as a template image of the patient's eyeball in the storage unit, an eyeball location tracking step of, during the treatment of the patient's eyeball, determining whether movement of the treatment image has occurred by comparing treatment images of the patient's eyeball in real time with the template image, and a control step of stopping the operation of the proton beam output device if the movement of the treatment image deviates from a preset tolerance range, and keeping operation of the proton beam output device normal if the movement of the treatment image is within the tolerance range. | 10-15-2009 |
| 20090074727 | METHOD OF TREATING SOLID TUMOR - The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method. | 03-19-2009 |
| 20090023894 | Neutralizing Antibody Against HGF - The neutralizing antibody against HGF binding to the inventive neutralizable epitope of HGF is capable of neutralizing HGF as a single agent, and can be effectively used for preventing and treating intractable diseases and cancers that are caused by binding of HGF to its receptor Met. | 01-22-2009 |
